Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome

N Engl J Med. 2014 Jan 30;370(5):486-8. doi: 10.1056/NEJMc1304828.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • CCR5 Receptor Antagonists*
  • Cyclohexanes / therapeutic use*
  • Female
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / drug therapy*
  • Immune Reconstitution Inflammatory Syndrome / virology
  • Immunocompromised Host*
  • JC Virus*
  • Leukoencephalopathy, Progressive Multifocal / drug therapy*
  • Leukoencephalopathy, Progressive Multifocal / etiology
  • Maraviroc
  • Multiple Sclerosis, Relapsing-Remitting / complications
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Natalizumab
  • Receptors, CCR5 / immunology
  • Triazoles / therapeutic use*
  • Viral Load

Substances

  • Antibodies, Monoclonal, Humanized
  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • Natalizumab
  • Receptors, CCR5
  • Triazoles
  • Maraviroc